Publication:
Economic Evaluation of Nirmatrelvir/Ritonavir Among Adults Against Hospitalization During the Omicron Dominated Period in Malaysia: A Real-World Evidence Perspective

Simple item page
dc.contributor.authorEe Vien Low
dc.contributor.authorHoon Shien Teh
dc.contributor.authorNicholas Yee Liang Hing
dc.contributor.authorSuresh Kumar Chidambaram
dc.contributor.authorMohan Dass Pathmanathan
dc.contributor.authorWee Ric Kim
dc.contributor.authorWei Jia Lee
dc.contributor.authorZhi Wei Teh
dc.contributor.authorMaheshwara Rao Appannan
dc.contributor.authorShahanizan Mohd Zin
dc.contributor.authorFaizah Muhamad Zin
dc.contributor.authorSamha Bashirah Mohamed Amin
dc.contributor.authorMastura Ismail
dc.contributor.authorAzah Abdul Samad
dc.contributor.authorKalaiarasu M. Peariasamy
dc.date.accessioned2024-08-21T07:21:06Z
dc.date.available2024-08-21T07:21:06Z
dc.date.issued2024
dc.description.abstractBackground and objectives: Nirmatrelvir/ritonavir was administered orally to manage mild to moderate symptoms of COVID 19 in adult patients. The objectives of this study were to (i) evaluate the cost-efectiveness of prescribing nirmatrelvir/rito navir within 5 days of a COVID-19 illness in order to avert hospitalization within a 30-day period in the Malaysia setting; (ii) determine how variations in pricing and hospitalization rates will afect the cost-efectiveness of nirmatrelvir/ritonavir. Methods: The 30-day hospitalization related to COVID-19 was determined using 1 to 1 propensity score-matched real-world data in Malaysia from 14 July 2022 to 14 November 2022. To determine the total per-person costs related to COVID-19, we added the cost of drug (nirmatrelvir/ritonavir or control), clinic visits and inpatient care. Incremental cost-efectiveness ratio (ICER) per hospitalization averted was calculated. Results: Our cohort included 31,487 patients. The rate of hospitalization within 30 days was found to be 0.35% for the group treated with nirmatrelvir/ritonavir, and 0.52% for the control group. The nirmatrelvir/ritonavir group cost an additional MYR 1,625.72 (USD 358.88) per patient. This treatment also resulted in a reduction of 0.17% risk for hospitalization, which corresponded to an ICER of MYR 946,801.26 (USD 209,006.90) per hospitalization averted. Conclusion: In Malaysia, where vaccination rates were high, nirmatrelvir/ritonavir has been shown to be benefcial in the outpatient treatment of adults with COVID-19 who have risk factors; however, it was only marginally cost efective against hospitalization for healthy adults during the Omicron period.
dc.identifier.doihttps://doi.org/10.1007/s40801-024-00427-0
dc.identifier.urihttps://link.springer.com/article/10.1007/s40801-024-00427-0
dc.identifier.urihttps://repository.nih.gov.my/handle/123456789/975
dc.language.isoen
dc.publisherSpringer Link
dc.relation.ispartofDrugs - Real World Outcomes
dc.relation.issn2199-1154
dc.titleEconomic Evaluation of Nirmatrelvir/Ritonavir Among Adults Against Hospitalization During the Omicron Dominated Period in Malaysia: A Real-World Evidence Perspective
dc.typejournal-article
dspace.entity.typePublication
oaire.citation.issue2
oaire.citation.volume11
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Economic Evaluation of Nirmatrelvir_Ritonavir Among Adults Against Hospitalization During the Omicron Dominated Period in Malaysia_A Real World Evidence Perspective - PUAN TEH HOON SHIEN (CRC).pdf
Size:
814.87 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Selected Article of Journal (ICR)